EU agency recommends Sanofi, Merck pediatric vaccine

LONDON Fri Feb 22, 2013 7:31am EST

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) - RTXCK2X

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009.

Credit: Reuters/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH) - RTXCK2X

Related Topics

LONDON (Reuters) - The European Medicines Agency recommended approval of Hexyon, a new 6-in-1 pediatric vaccine from Sanofi Pasteur MSD, a joint venture between Merck and Sanofi, the companies said on Friday.

The new vaccine protects against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Pictures